Author + information
- Received February 17, 2019
- Revision received March 26, 2019
- Accepted April 2, 2019
- Published online September 2, 2019.
- Iosif Xenogiannis, MDa,b,
- Peter Tajti, MDa,b,c,
- Allison B. Hall, MDa,
- Khaldoon Alaswad, MDd,
- Stéphane Rinfret, MDe,
- William Nicholson, MDf,
- Dimitri Karmpaliotis, MDg,
- Kambis Mashayekhi, MDh,
- Sergey Furkalo, MDi,
- João L. Cavalcante, MDa,
- M. Nicholas Burke, MDa and
- Emmanouil S. Brilakis, MD, PhDa,b,∗ ()
- aMinneapolis Heart Institute, Abbott Northwestern Hospital, Center for Complex Coronary Interventions, Minneapolis, Minnesota
- bMinneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Complex Coronary Artery Disease Science Center, Minneapolis, Minnesota
- cUniveristy of Szeged, Department of Invasive Cardiology, Second Department of Internal Medicine and Cardiology Center, Szeged, Hungary
- dHenry Ford Hospital, Department of Interventional Cardiology, Detroit, Michigan
- eMcGill University Health Centre, McGill University, Department of Interventional Cardiology, Montreal, Quebec, Canada
- fWellSpan Cardiology, Department of Interventional Cardiology, York, Pennsylvania
- gColumbia University Medical Center, Center for Interventional Vascular Therapy, New York, New York
- hDepartment of Cardiology and Angiology II University Heart Center Freiburg Bad Krozingen, Bad Krozingen, Germany
- iDepartment of Endovascular Surgery and Angiography, National Institute of Surgery and Transplantology of AMS of Ukraine, Kiev, Ukraine
- ↵∗Address for correspondence:
Dr. Emmanouil S. Brilakis, Minneapolis Heart Institute, 920 East 28th Street #300, Minneapolis, Minnesota 55407.
• Additional revascularization is often needed after coronary artery bypass graft surgery and carries increased risk.
• Optimal saphenous vein graft percutaneous coronary intervention requires embolic protection devices and vasodilators.
• If feasible, recanalization of the native coronary artery is preferred over bypass graft recanalization.
• Novel technical developments and pharmacotherapy are needed to improve outcomes after coronary bypass graft surgery.
Patients who undergo coronary bypass graft surgery often require subsequent cardiac catheterization and repeat coronary revascularization. Saphenous vein graft lesions have high rates for distal embolization that can be reduced with use of embolic protection devices. They also have high restenosis rates, which are similar with drug-eluting and bare-metal stents. Percutaneous coronary interventions of native coronary arteries is generally preferred over saphenous vein graft interventions, but can often be complex, requiring expertise and specialized equipment. Prolonged dual-antiplatelet therapy and close monitoring can help optimize subsequent clinical outcomes.
Dr. Alaswad has received consulting fees from Terumo and Boston Scientific; and has been an unpaid consultant for Abbott Laboratories. Dr. Rinfret has received speaker and proctorship honoraria from Boston Scientific, Abbott Vascular Canada, Medtronic Canada, SoundBite, and Terumo US. Dr. Nicholson has been a proctor, consultant, and advisory board member for Abbott Vascular, Boston Scientific, and Medtronic. Dr. Karmpaliotis has received speaker honoraria from Abbott Vascular and Boston Scientific. Dr. Mashayekhi has received consulting/speaker fees from Ashai Intecc, AstraZeneca, Biotronik, Boston Scientific, Cardinal Health, Daiichi-Sankyo, Medtronic, Teleflex, and Terumo. Dr. Cavalcante has received research grants from Medtronic and Abbott; and has been a consultant/speaker for Medtronic, Circle Cardiovascular Imaging, and Siemens Inc. Dr. Burke has received consulting and speaker honoraria from Abbott Vascular and Boston Scientific. Dr. Brilakis has received consulting/speaker honoraria from Abbott Vascular, American Heart Association (associate editor: Circulation), Boston Scientific, Cardiovascular Innovations Foundation (board of directors), CSI, Elsevier, GE Healthcare, InfraRedx, and Medtronic; has received research support from Regeneron and Siemens; is a shareholder in MHI Ventures; and has served on the board of trustees for the Society of Cardiovascular Angiography and Interventions. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received February 17, 2019.
- Revision received March 26, 2019.
- Accepted April 2, 2019.
- 2019 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.